BioWorld

July 16, 2003

MIT Scientist Rejects Mutagenic Cause of Neoplasms; Espouses Outside Factors Over Mutations

Industry Reps Continue Debating The Issue Of Generic Biologics

Several Hybridon Presentations Highlight Early Cancer Platform

Other News To Note

Trimeris, Roche Increase Capacity For Fuzeon, Release More Data

Reports of increased global supplies of Fuzeon, coupled with longer-term data on the product, gave Trimeris Inc. a boost from investors eyeing higher earnings from early sales of the FDA-approved HIV drug. (BioWorld Today) Read More

Medivir, Boehringer Ingelheim Enter Potential EUR122M Alliance

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...